

Board Meeting in Public Tuesday, 30 September 2025

Title of Report	Governance Update				Agenda No.	5.1	
Nature of Report	⊠ Official			☐ Official Sensitive			
Author(s)	Silena Dominy, Company Secretary						
Lead Executive	Helen Gillan, Director of Quality and Governance						
Non-Executive Director Sponsor	Peter Wyman, Chair						
Presented for	□ Approval□ Assurance☑ Update						
Executive Summary							
This report provides the Board with an update on corporate governance matters in NHS Blood and Transplant (NHSBT).							
Previously Considered by							
N/A							
Recommendation	The Board is asked to note the report and endorse the re-appointment of Niamh McKenna as Independent Member of the ARGC.						
Risk(s) identified (Link to Board Assurance Framework Risks)							
BAF P11 Corporate Governance "There is a risk that the Board does not have full oversight of significant risk caused by ineffective systems or their application resulting in uninformed decision-making, a requirement for emergency management, sub-optimal outcomes and reputational damage" The frequent review of governance arrangements ensures continuous improvement and oversight reduces the likelihood of the Board not fulfilling its duties, or stepping outside of its powers, therefore strengthens governance.							
Strategic Objective(s) this paper relates to:							
☑ Collaborate with pa☑ Modernise our ope			☐ Invest in people and culture ☐ Drive innovation☐ Grow and diversify our donor base				
Annendices:							



1. Background

This report provides the Board with an update on Corporate Governance matters in NHSBT.

2. Board Level Policies

This meeting presents the following Board Level Policies for approval:

- BLP-S Health, Safety and Wellbeing Policy Statement of Intent (agenda item 4.1)
- BLP6 Environment and Net Zero Policy Statement (agenda item 4.3)

The Framework Agreement between the Department of Health and Social Care (DHSC) and NHSBT has been approved by DHSC and HM Treasury and has now been published on the .gov.uk website. The NHSBT website links to this.

3. Board Committee Terms of Reference Reviews

At the Board meeting in July 2025 the Board agreed amendments to the Terms of Reference of each of it's Sub-Committees, following reviews that had been carried out by the committees themselves. The further amendments to the Terms of Reference have been made and final versions of the Terms of Reference are in the Review Room for this meeting for information.

4. Board Appointments

Following the completion of pre-appointment and Fit and Proper Person checks, DHSC have confirmed that:

- Caroline Serfass has been re-appointed as a Non-Executive Director of NHSBT for 3 years from 1 May 2026, being the day following the expiry of her current term.
- Rachel Jones current term of office as a Non-Executive Director of NHSBT which expires on 30 April 2026, has been extended for a further 10 months from 1 May 2026.

Following completion of a three-year honorary term of office as Independent Member of the Audit, Risk and Governance Committee, Niamh McKenna has been re-appointed to this role for a further three-year term. The Board is asked to endorse this appointment.

5. Fit and Proper Person Regulations

Annual checks for all Board members were completed at the end of July 2025 and the Chair and Senior Independent Director (in relation to the Chair) have certified the conclusion of the annual process under the Fit and Proper Persons Testing Framework.

6. Board Knowledge Development

The Board Knowledge Development Plan can be found in the Review Room for this meeting, for information.



7. Stakeholder Engagement

Information in relation to engagements of the Chair and Chief Executive with stakeholders and DHSC since the last meeting is included in the Review Room for this meeting.